Intech Investment Management LLC Purchases 25,828 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Intech Investment Management LLC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 72.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 61,531 shares of the specialty pharmaceutical company’s stock after buying an additional 25,828 shares during the quarter. Intech Investment Management LLC’s holdings in Supernus Pharmaceuticals were worth $3,058,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of SUPN. Rubric Capital Management LP bought a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth $21,908,000. Woodline Partners LP raised its position in Supernus Pharmaceuticals by 63.5% in the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after buying an additional 490,835 shares during the last quarter. Bank of America Corp DE raised its position in Supernus Pharmaceuticals by 67.1% in the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after buying an additional 338,584 shares during the last quarter. UBS Group AG raised its position in Supernus Pharmaceuticals by 137.6% in the 3rd quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock valued at $25,812,000 after buying an additional 312,775 shares during the last quarter. Finally, Sofinnova Investments Inc. raised its position in Supernus Pharmaceuticals by 53.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock valued at $25,192,000 after buying an additional 278,575 shares during the last quarter.

Insiders Place Their Bets

In other news, Director Georges Gemayel sold 8,787 shares of the firm’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $53.00, for a total transaction of $465,711.00. Following the completion of the sale, the director directly owned 27,277 shares of the company’s stock, valued at $1,445,681. This trade represents a 24.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 7,250 shares of the firm’s stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $49.60, for a total value of $359,600.00. Following the sale, the vice president directly owned 17,044 shares of the company’s stock, valued at approximately $845,382.40. This represents a 29.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 116,406 shares of company stock valued at $5,911,086. 8.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on SUPN. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 23rd. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $62.17.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $44.07 on Wednesday. Supernus Pharmaceuticals, Inc. has a 1 year low of $30.83 and a 1 year high of $59.68. The firm has a market cap of $2.56 billion, a PE ratio of -86.41, a P/E/G ratio of 0.97 and a beta of 0.55. The stock has a fifty day moving average price of $49.61 and a 200-day moving average price of $49.58.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.